Cancer Epidemiology
Volume 33, Issue 3 , Pages 212-215 , October 2009

A projection of benefits due to fecal occult blood test for colorectal cancer

  • Dongfeng Wu

      Affiliations

    • Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY 40202, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 502 852 1888; fax: +1 502 852 3294.
    • ,
  • Diane Erwin

      Affiliations

    • Information Management Services, Inc., Rockville, MD 20852, USA
    • ,
  • Gary L. Rosner

      Affiliations

    • Department of Biostatistics and Applied Mathematics, M. D. Anderson Cancer Center, Houston, TX 77030, USA

,Accepted 11 August 2009.

References 

  1. Wu D, Rosner GL, Broemeling LD. Bayesian inference for the lead time in periodic cancer screening. Biometrics. 2007;63(3):873–880
  2. Cancer facts and figures. American Cancer Society; 2008. http://www.cancer.org/downloads/stt/2008cafffinalsecured.pdf.
  3. SEER Fast Stats Results, NIH. http://seer.cancer.gov/statfacts/html/colorect.html.
  4. Anderson WF, Guyton KA, Hiatt RA, Vernon SW, Levin B, Hawk E. Colorectal cancer screening for person at average risk. J Natl Cancer Inst. 2002;94:1126–1133
  5. Church TR. Offering patients colorectal cancer screening. J Natl Cancer Inst. 2005;97:328–329
  6. Wu D, Erwin D, Rosner GL. Estimating key parameters in FOBT screening for colorectal cancer. Cancer Causes Control. 2009;(20):41–46
  7. Wu D, Rosner GL, Broemeling LD. MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening. Biometrics. 2005;61(4):1056–1063
  8. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434–437
  9. Launoy G, Smith TC, Duffy SW, Bouvier V. Colorectal cancer massscreening: estimation of fecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int. J. Cancer. 1997;73:220–224
  10. Prevost TC, Launoy G, Duffy S, Chen HH. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches. Am J Epidemiol. 1998;148:609–619
  11. Walter SD, Day NE. Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol. 1983;118:856–886
  12. Prorok PC. Bounded recurrence times and lead time in the design of a repetitive screening program. J Appl Prob. 1982;19:10–19
  13. Straatman H, Peer P, Verbeek A. Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group. Biometrics. 1997;53:217–229
  14. Kafadar K, Prorok PC. Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials. Stat Med. 2003;22:83–111
  15. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103(6):1541–1549
  16. Launoy G, Berchi C. Advantage of immunochemical fecal occult blood test in screening for colorectal cancer. Bull Cancer. 2005;9:885–890

PII: S1877-7821(09)00100-3

doi: 10.1016/j.canep.2009.08.001

Cancer Epidemiology
Volume 33, Issue 3 , Pages 212-215 , October 2009

Article Tools

* Image Usage & Resolution